期刊
JOURNAL OF NEUROLOGY
卷 251, 期 9, 页码 1080-1084出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-004-0481-5
关键词
amyotrophic lateral sclerosis; motor neuron disease; rasagiline; G93A animals; experimental therapeutics
Rasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20% in a dose-dependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据